Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508298 · ClinicalTrials.gov registry record · NA
Surrogate Markers of Portal Pressure
A NA study, sponsored by VA Connecticut Healthcare System.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT02508298: Completed NA study, sponsored by VA Connecticut Healthcare System.
NCT02508298 is a NA study that has completed, run by VA Connecticut Healthcare System. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508298, a NA study, has completed, sponsored by VA Connecticut Healthcare System.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a prospective longitudinal study that will evaluate if changes (pre and post therapy) in indocyanine green (ICG) retention test and liver stiff ness (LS) and spleen stiffness (SS) as measured by acoustic radiofrequency impulse (ARFI) correlate with changes in portal pressure as determined by the hepatic vein pressure gradient (HVPG) in patients with compensated hepatitis C virus (HCV) cirrhosis undergoing antiviral therapy.
Primary Outcome
Indocyanine Green will be obtained , this will be conducted before and after treatment for hepatitis c and is measured in mg/dl
Interventions
- PROCEDURE HVPG
- DRUG Indocyanine Green Retention test
- DEVICE Liver stiffness measurement
- DEVICE Spleen stiffness measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-07 |
| Phase | NA |
What the finished NCT02508298 record still lists
NCT02508298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which HVPG is the first listed.
NCT02508298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02508298 about?
NCT02508298 is a clinical study titled "Surrogate Markers of Portal Pressure". This is a prospective longitudinal study that will evaluate if changes (pre and post therapy) in indocyanine green (ICG) retention test and liver stiff ness (LS) and spleen stiffness (SS) as measured by acoustic radiofrequency impulse (ARFI) correlate with changes in portal pressure as determined by...
What is the current status of trial NCT02508298?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2014-04. Estimated completion is 2019-07.
What interventions are being tested in trial NCT02508298?
The interventions under investigation include: HVPG (PROCEDURE), Indocyanine Green Retention test (DRUG), Liver stiffness measurement (DEVICE), Spleen stiffness measurement (DEVICE).
Who is sponsoring clinical trial NCT02508298?
This trial is sponsored by VA Connecticut Healthcare System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02508298's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia